BostonGene
BostonGene: Pioneering biomedical software for personalized cancer therapy decisions.
Founded
2015BostonGene: Pioneering biomedical software for personalized cancer therapy decisions.
BostonGene Corporation, founded with the mission to revolutionize cancer treatment through advanced biomedical software, focuses on personalized therapy decisions. The company leverages cutting-edge technology to provide comprehensive patient analysis, aiming to enhance the precision and efficacy of cancer treatments. Their core products and services include genomic and transcriptomic profiling, immune microenvironment analysis, and advanced computational biology tools, primarily targeting oncologists and healthcare providers in the oncology sector.
Notable figures affiliated with BostonGene include leading scientists and medical professionals who contribute to its innovative approach. The company has garnered significant attention and investment from prominent venture capital firms in the biotech industry. Key achievements include winning the GRASP Advocate Choice Award at the ASCO Annual Meeting, highlighting their impact on cancer research and patient care. BostonGene's work has significantly advanced personalized cancer treatment, offering new hope and pathways for patients with complex cancer diagnoses.
Companies similar to BostonGene include Seven Bridges, MatchTx, Personalis and Genomenon.
BostonGene was founded in 2015.
BostonGene's headquarters is located in Waltham, MA, US.
BostonGene's most recent funding round was for $150M (USD) in April 2022.
As of Apr 6, 2022, BostonGene has disclosed funding of $200M (USD). Undisclosed round amounts are excluded.
BostonGene has 375 employees as of Feb 4, 2024.
Genomenon
genomenon.com
